Publications
Awor P, Coppée R, Khim N, Rondepierre L, Roesch C, Khean C, Kul C, Eam R, Lorn T, Athieno P, Kimera J, Balikagala B, Odongo-Aginya E.I, Anywar D.A, Mita T, Clain J, Ringwald P, Signorell A, Lengeler C, Burri C, Ariey F, Hetzel M.W, Witkowski B. Indigenous emergence and spread of kelch13 C469Y artemisinin-resistant Plasmodium falciparum in Uganda. Antimicrob Agents Chemother. 2024;68(8):e0165923. DOI: 10.1128/aac.01659-23
Karim A, Burri C, Kila J.S, Bambwelo N, Bakukulu J.T, de Savigny D. Systems thinking for supply chains: identifying bottlenecks using process mapping of a child health intervention in the Democratic Republic of the Congo (DRC). Systems. 2024;12(4):137. DOI: 10.3390/systems12040137
Journal Article
Nebie E.I, van Eeuwijk P, Sawadogo H.N, Reus E, Utzinger J, Burri C. Operational differences between product development partnership, pharmaceutical industry, and investigator initiated clinical trials. Trop Med Infect Dis. 2024;9(3):56. DOI: 10.3390/tropicalmed9030056
Blum J, Staehelin C, Neumayr A, Chappuis F, Burri C. Schlafkrankheit: der gefährliche Schlaf nach dem Erfolg. Swiss Med Forum. 2023;23(3):846–848. DOI: 10.4414/smf.2023.09243
Journal Article
Brunner N.C, Karim A, Athieno P, Kimera J, Tumukunde G, Angiro I, Signorell A, Delvento G, Lee T.T, Lambiris M, Ogwal A, Nakiganda J, Mpanga F, Kagwire F, Amutuhaire M, Burri C, Lengeler C, Awor P, Hetzel M.W. Starting at the community: treatment-seeking pathways of children with suspected severe malaria in Uganda. PLOS Glob Public Health. 2023;3(7):e0001949. DOI: 10.1371/journal.pgph.0001949
Burri C, Mäser P, Chappuis F. Human African trypanosomiasis. In: Farrar J,Hotez P.J,Junghanss T,Kang G,Lalloo D,White N.J,Garcia P.J, eds. Manson's Tropical Diseases, 623-635. Amsterdam: Elsevier, 2023. DOI: 10.1016/B978-0-7020-7959-7.00051-8
Book Section
Hetzel M.W, Awor P, Tshefu A, Omoluabi E, Burri C, Signorell A, Lambiris M.J, Visser T, Cohen J.M, Buj V, Lengeler C. Pre-referral rectal artesunate: no cure for unhealthy systems. Lancet Infect Dis. 2023;23(6):e213-e217. DOI: 10.1016/S1473-3099(22)00762-9
Hetzel M.W, Okitawutshu J, Tshefu A, Omoluabi E, Awor P, Signorell A, Kwiatkowski M, Lambiris M.J, Visser T, Cohen J.M, Buj V, Burri C, Lengeler C. Pre-referral rectal artesunate is no "magic bullet" in weak health systems. BMC Med. 2023;21:119. DOI: 10.1186/s12916-023-02777-y
Kaboré J.M.T, Siribié M, Hien D, Soulama I, Barry N, Baguiya A, Tiono A.B, Burri C, Tchouatieu A.M, Sirima S.B. Feasibility and acceptability of a strategy deploying multiple first-line artemisinin-based combination therapies for uncomplicated malaria in the health district of Kaya, Burkina Faso. Trop Med Infect Dis. 2023;8(4):195. DOI: 10.3390/tropicalmed8040195
Lambiris M.J, Venga G.N, Ssempala R, Balogun V, Galactionova K, Musiitwa M, Kagwire F, Olosunde O, Emedo E, Luketa S, Sangare M, Buj V, Delvento G, Tshefu A, Okitawutshu J, Omoluabi E, Awor P, Signorell A, Hetzel M.W, Lee T.T, Brunner N.C, Cereghetti N, Visser T, Napier H.G, Burri C, Lengeler C. Health system readiness and the implementation of rectal artesunate for severe malaria in sub-Saharan Africa: an analysis of real-world costs and constraints. Lancet Glob Health. 2023;11(2):e256-e264. DOI: 10.1016/S2214-109X(22)00507-1
Mäser P, Bernhard S, Brun R, Burri C, Gagneux S, Hetzel M.W, Kaiser M, Lengeler C, Pluschke G, Reus E, Rottmann M, Utzinger J, Warryn L, Wittlin S, Keiser J. Key contributions by the Swiss Tropical and Public Health Institute towards new and better drugs for tropical diseases. Chimia (Aarau). 2023;77(9):593-606. DOI: 10.2533/chimia.2023.593
Meier L, Antillón M, Burri C, Chitnis N, Endriss Y, Keiser J, Moore S, Müller P, Penny M, Voss T.S, Mäser P, Utzinger J. Repurposing know-how for drug development: case studies from the Swiss Tropical and Public Health Institute. Chimia (Aarau). 2023;77(9):582-592. DOI: 10.2533/chimia.2023.582
Menang O, Kümmerle A, Maigetter K, Burri C. Strategies and interventions to strengthen pharmacovigilance systems in low-income and middle-income countries: a scoping review. BMJ Open. 2023;13(9):e071079. DOI: 10.1136/bmjopen-2022-071079
Nébié E.I, Sawadogo H.N, van Eeuwijk P, Signorell A, Reus E, Utzinger J, Burri C. Opportunities and challenges for decentralised clinical trials in sub-Saharan Africa: a qualitative study. BMJ Open. 2023;13(9):e075903. DOI: 10.1136/bmjopen-2023-075903
Okitawutshu J, Tshefu A, Kalenga J.C, Delvento G, Burri C, Hetzel M.W, Lengeler C, Signorell A. Assessing caregivers' perceptions of treatment-seeking for suspected severe malaria in the Democratic Republic of the Congo. Malar J. 2023;22:308. DOI: 10.1186/s12936-023-04737-6
Signorell A, Awor P, Okitawutshu J, Tshefu A, Omoluabi E, Hetzel M.W, Athieno P, Kimera J, Tumukunde G, Angiro I, Kalenga J.C, Akano B.K, Ayodeji K, Okon C, Yusuf O, Delvento G, Lee T.T, Brunner N.C, Lambiris M.J, Okuma J, Cereghetti N, Buj V, Visser T, Napier H.G, Lengeler C, Burri C. Health worker compliance with severe malaria treatment guidelines in the context of implementing pre-referral rectal artesunate in the Democratic Republic of the Congo, Nigeria, and Uganda: an operational study. PLoS Med. 2023;20(2):e1004189. DOI: 10.1371/journal.pmed.1004189
van Zyl-Hermann D, Hammel T, Burri C, Chenal J, Fink G, Konou A.A, Nébié E.I, Osei Afriyie D, Pessoa Colombo V, Utzinger J, Tischler J. Examining African contributions to global health: reflections on knowledge circulation and innovation. Glob Public Health. 2023;18(1):2118343. DOI: 10.1080/17441692.2022.2118343
Awor P, Kimera J, Athieno P, Tumukunde G, Okitawutshu J, Tshefu A, Omoluabi E, Signorell A, Brunner N, Kalenga J.C, Akano B, Ayodeji K, Okon C, Yusuf O, Delvento G, Lee T, Burri C, Lengeler C, Hetzel M.W. Acceptability of pre-referral rectal artesunate for severe malaria in children under 5 years by health workers and caregivers in the Democratic Republic of the Congo, Nigeria and Uganda. Malar J. 2022;21:322. DOI: 10.1186/s12936-022-04348-7
Awor P, Kimera J, Brunner N.C, Athieno P, Tumukunde G, Angiro I, Signorell A, Delvento G, Lee T, Amutuhaire M, Opigo J, Kaggwa F.M, Kagwire F, Nakiganda J, Burri C, Lengeler C, Hetzel M.W. Care seeking and treatment of febrile children with and without danger signs of severe disease in northern Uganda: results from three household surveys (2018-2020). Am J Trop Med Hyg. 2022;107(4):934–938. DOI: 10.4269/ajtmh.21-1132
Bernhard S, Kaiser M, Burri C, Mäser P. Fexinidazole for human African trypanosomiasis, the fruit of a successful public-private partnership. Diseases. 2022;10(4):90. DOI: 10.3390/diseases10040090
Brunner N.C, Omoluabi E, Awor P, Okitawutshu J, Tshefu Kitoto A, Signorell A, Akano B, Ayodeji K, Okon C, Yusuf O, Athieno P, Kimera J, Tumukunde G, Angiro I, Kalenga J.C, Delvento G, Lee T.T, Lambiris M.J, Ross A, Cereghetti N, Visser T, Napier H.G, Buj V, Burri C, Lengeler C, Hetzel M.W. Prereferral rectal artesunate and referral completion among children with suspected severe malaria in the Democratic Republic of the Congo, Nigeria and Uganda. BMJ Glob Health. 2022;7(5):e008346. DOI: 10.1136/bmjgh-2021-008346
De Pretto-Lazarova A, Fuchs C, van Eeuwijk P, Burri C. Defining clinical trial quality from the perspective of resource-limited settings: a qualitative study based on interviews with investigators, sponsors, and monitors conducting clinical trials in sub-Saharan Africa. PLoS Negl Trop Dis. 2022;16(1):e0010121. DOI: 10.1371/journal.pntd.0010121
Hetzel M.W, Okitawutshu J, Tshefu A, Omoluabi E, Awor P, Signorell A, Brunner N.C, Kalenga J.C, Akano B.K, Ayodeji K, Okon C, Yusuf O, Athieno P, Kimera J, Tumukunde G, Angiro I, Delvento G, Lee T.T, Lambiris M.J, Kwiatkowski M, Cereghetti N, Visser T, Napier H.G, Cohen J.M, Buj V, Burri C, Lengeler C. Effectiveness of rectal artesunate as pre-referral treatment for severe malaria in children under 5 years of age: a multi-country observational study. BMC Med. 2022;20:343. DOI: 10.1186/s12916-022-02541-8
Kaboré J.M.T, Siribié M, Hien D, Soulama I, Barry N, Nombré Y, Dianda F, Baguiya A, Tiono A.B, Burri C, Tchouatieu A.M, Sirima S.B. Attitudes, practices, and determinants of community care-seeking behaviours for fever/malaria episodes in the context of the implementation of multiple first-line therapies for uncomplicated malaria in the health district of Kaya, Burkina Faso. Malar J. 2022;21:155. DOI: 10.1186/s12936-022-04180-z
Lengeler C, Burri C, Awor P, Athieno P, Kimera J, Tumukunde G, Angiro I, Tshefu A, Okitawutshu J, Kalenga J.-C, Omoluabi E, Akano B, Ayodeji K, Okon C, Yusuf O, Brunner N.C, Delvento G, Lee T, Lambiris M.J, Visser T, Napier H.G, Cohen J.M, Buj V, Signorell A, Hetzel Manuel W, Caramal Consortium. Community access to rectal artesunate for malaria (CARAMAL): a large-scale observational implementation study in the Democratic Republic of the Congo, Nigeria and Uganda. PLoS Glob Public Health. 2022;2(9):e0000464. DOI: 10.1371/journal.pgph.0000464
Journal Article
Ntamabyaliro N.Y, Burri C, Lula Y.N, Nzolo D.B, Engo A.B, Ngale M.A, Situakibanza H.N, Mukomena E.S, Mesia G.K, Mampunza S.M, Tona G.L. Determinants of patients' adherence to malaria treatment in the Democratic Republic of the Congo. Trop Med Infect Dis. 2022;7(7):138. DOI: 10.3390/tropicalmed7070138
Okitawutshu J, Signorell A, Kalenga J.C, Mukomena E, Delvento G, Burri C, Mwaluke F, Buj V, Sangare M, Luketa S, Brunner N, Lee T, Hetzel M, Lengeler C, Tshefu A. Key factors predicting suspected severe malaria case management and health outcomes: an operational study in the Democratic Republic of the Congo. Malar J. 2022;21:274. DOI: 10.1186/s12936-022-04296-2
Awor P, Khim N, Coppée R, Rondepierre L, Roesch C, Khean C, Kul C, Eam R, Lorn T, Athieno P, Kimera J, Clain J, Ringwald P, Signorell A, Lengeler C, Burri C, Ariey F, Hetzel M.W, Witkowski B. Clonal expansion of artemisinin-resistant Plasmodium falciparum in Uganda is associated with substandard treatment practices. Lancet. 2021(in press). DOI: 10.2139/ssrn.3974542
Journal Article
Burri C, Gerold J. Executive summary: external assessment of Unitaid’s human subject research management. Basel: Swiss TPH, 2021
Report
Das A.M, Chitnis N, Burri C, Paris D.H, Patel S, Spencer S.E.F, Miaka E.M, Castaño M.S. Modelling the impact of fexinidazole use on human African trypanosomiasis (HAT) transmission in the Democratic Republic of the Congo. PLoS Negl Trop Dis. 2021;15(11):e0009992. DOI: 10.1371/journal.pntd.0009992
De Pretto-Lazarova A, Brancati-Badarau D.O, Burri C. Transparent reporting of recruitment and informed consent approaches in clinical trials recruiting children with minor parents in sub-Saharan Africa: a secondary analysis based on a systematic review. BMC Public Health. 2021;21:1473. DOI: 10.1186/s12889-021-11079-y
Kümmerle A, Schmid C, Bernhard S, Kande V, Mutombo W, Ilunga M, Lumpungu I, Mutanda S, Nganzobo P, Tete D.N, Kisala M, Burri C, Blesson S, Valverde Mordt O. Effectiveness of Nifurtimox Eflornithine Combination Therapy (NECT) in T. b. gambiense second stage sleeping sickness patients in the Democratic Republic of Congo: report from a field study. PLoS Negl Trop Dis. 2021;15(11):e0009903. DOI: 10.1371/journal.pntd.0009903
Kümmerle A, Sikalengo G, Vanobberghen F, Ndege R.C, Foe G, Schlaeppi C, Burri C, Battegay M, Paris D.H, Glass T.R, Weisser M, Marzolini C, Kiularco Study Group. Recognition and management of clinically significant drug-drug interactions between antiretrovirals and co-medications in a cohort of people living with HIV in rural Tanzania: a prospective questionnaire-based study. J Antimicrob Chemother. 2021;76(10):2681-2689. DOI: 10.1093/jac/dkab254
Lee T.T, Omoluabi E, Ayodeji K, Yusuf O, Okon C, Brunner N.C, Delvento G, Signorell A, Lambiris M, Kwiatkowski M, Burri C, Lengeler C, Emedo E, Cheshi F, Hetzel M.W. Treatment-seeking for children with suspected severe malaria attending community health workers and primary health centres in Adamawa State, Nigeria. medRxiv. 2021(in press). DOI: 10.1101/2021.12.01.21267130
Journal Article
Ntamabyaliro N.Y, Burri C, Lula Y.N, Ishoso D, Engo A.B, Ngale M.A, Liwono J.Y, Mukomena E.S, Mesia G.K, Mampunza S.M, Tona G.L. Knowledge of antimalarials and health seeking behaviour of households in case of suspected malaria in Democratic Republic of the Congo. Trop Med Infect Dis. 2021;6(3):157. DOI: 10.3390/tropicalmed6030157
Signorell A, Saric J, Appenzeller-Herzog C, Ewald H, Burri C, Goetz M, Gerold J. Methodological approaches for conducting follow-up research with clinical trial participants: a scoping review and expert interviews. Trials. 2021;22:961. DOI: 10.1186/s13063-021-05866-6
Blum A, Mudji J, Grize L, Burri C, Zellweger M.J, Blum J. Sleeping hearts: 12 years after a follow up study on cardiac findings due to sleeping sickness. One Health. 2020;11:100182. DOI: 10.1016/j.onehlt.2020.100182
Burri C. Sleeping sickness at the crossroads. Trop Med Infect Dis. 2020;5(2):57. DOI: 10.3390/tropicalmed5020057
Burri C, ed. Human African trypanosomiasis (sleeping sickness): the road to elimination revisited - achievements and remaining challenges. Basel: MDPI, 2020. Printed edition of the special issue published in . DOI: 10.3390/books978-3-03928-964-6
Edited Book
De Pretto-Lazarova A, Brancati-Badarau D.O, Burri C. Informed consent approaches for clinical trial participation of infants with minor parents in sub-Saharan Africa: a systematic review. PLoS One. 2020;15(8):e0237088. DOI: 10.1371/journal.pone.0237088
Dickie E.A, Giordani F, Gould M.K, Mäser P, Burri C, Mottram J.C, Rao S.P.S, Barrett M.P. New drugs for human African trypanosomiasis: a twenty first century success story. Trop Med Infect Dis. 2020;5:29. DOI: 10.3390/tropicalmed5010029
Mudji J, Blum A, Grize L, Wampfler R, Ruf M.T, Cnops L, Nickel B, Burri C, Blum J. Gambiense human African trypanosomiasis sequelae after treatment: a follow-up study 12 years after treatment. Trop Med Infect Dis. 2020;5(1):10. DOI: 10.3390/tropicalmed5010010
Seixas J, Atouguia J, Josenando T, Vatunga G, Bilenge C.M.M, Lutumba P, Burri C. Clinical study on the melarsoprol-related encephalopathic syndrome: risk factors and HLA association. Trop Med Infect Dis. 2020;5(1):5. DOI: 10.3390/tropicalmed5010005
Mudji J, Benhamou J, Mwamba-Miaka E, Burri C, Blum J. The flipside of eradicating a disease; human African trypanosomiasis in a woman in rural Democratic Republic of Congo: a case report. Trop Med Infect Dis. 2019;4(4):142. DOI: 10.3390/tropicalmed4040142
Nzolo D, Kümmerle A, Lula Y, Ntamabyaliro N, Engo A, Mvete B, Liwono J, Lusakibanza M, Mesia G, Burri C, Mampunza S, Tona G. Development of a pharmacovigilance system in a resource-limited country: the experience of the Democratic Republic of Congo. Ther Adv Drug Saf. 2019;10:2042098619864853. DOI: 10.1177/2042098619864853
Kümmerle A, Akakpo S, Liwono J, Duparc S, Burri C, Stergachis A. Drug utilization and drug-drug interaction studies in the field: examples of South-North collaboration projects. Drug Safety, 2018;41(11):1120-1121
Conference Paper
Lengeler C, Hetzel M, Signorell A, Awor P, Tshefu A, Okitawutshu J, Omoluabi E, Nepomnyashchiy L, Fast J, Ramachandra S, Goldstein R, Buj V, Burri C. Introducing rectal artesunate in community settings and evaluating its impact. 7th MIM Pan African Malaria Conference. Dakar, Senegal, 2018
Conference Paper
Ntamabyaliro N.Y, Burri C, Nzolo D.B, Engo A.B, Lula Y.N, Mampunza S.M, Nsibu C.N, Mesia G.K, Kayembe J.N, Likwela J.L, Kintaudi L.M, Tona G.L. Drug use in the management of uncomplicated malaria in public health facilities in the Democratic Republic of the Congo. Malar J. 2018;17:189. DOI: 10.1186/s12936-018-2332-3
Signorell A, Hetzel M, Awor P, Tshefu A, Okitawutshu J, Omoluabi E, Nepomnyashchiy L, Burri C, Lengeler C. CARAMAL: addressing the remaining burden of malaria deaths by optimizing the use of rectla artesunate. 7th MIM Pan African Malaria Conference. Dakar, Senegal, 2018
Conference Paper
Simon A, Marzolini C, Vanobbergen F, Burri C, Kümmerle A. Reporting of qt interval prolongation and torsade de pointe for HIV-antiretrovirals in vigibase: focus on potential drug-drug interactions. Drug Safety, 2018;41(11):1178-1179
Conference Paper
Burri C, Blum J. Human African trypanosomiasis. In: Cohen Jonathan,Powderly William G,Opal Steven M, eds. Infectious Diseases. 2, 966-970;1761-1762: Elsevier, 2017
Book Section
Kümmerle A, Mäder M, Sartori D, Lazarova A, Urich M, Dodoo A, Olsson S, Burri C. Contribution of adverse events reporting of HIV antiretrovirals to VigiBase: comparison between sub-Saharan Africa and the rest of the world. Drug Safety. 2017;40(10):987-988
Journal Item
Kümmerle A, Sartori D, Maeder M, Lazarova A, Urich M, Dodoo A, Olsson S, Burri C. Spontaneous reporting characteristics of HIV antiretrovirals in vigibase: disproportionate analysis between sub-Saharan Africa and the rest of the world. Drug Saf, 2017;40(10):988-989
Conference Paper
Vischer N, Pfeiffer C, Kealy J, Burri C. Increasing protocol suitability for clinical trials in sub-Saharan Africa: a mixed methods study. Glob Health Res Policy. 2017;2:11. DOI: 10.1186/s41256-017-0031-1
Journal Article
Vischer N, Pfeiffer C, Limacher M, Burri C. "You can save time if..."-a qualitative study on internal factors slowing down clinical trials in sub-Saharan Africa. PLoS One. 2017;12(3):e0173796. DOI: 10.1371/journal.pone.0173796
Burri C, Yeramian P.D, Allen J.L, Merolle A, Serge K.K, Mpanya A, Lutumba P, Mesu V.K, Bilenge C.M, Lubaki J.P, Mpoto A.M, Thompson M, Munungu B.F, Manuel F, Josenando T, Bernhard S.C, Olson C.A, Blum J, Tidwell R.R, Pohlig G. Efficacy, safety, and dose of pafuramidine, a new oral drug for treatment of first stage sleeping sickness, in a phase 2a clinical study and phase 2b randomized clinical studies. PLoS Negl Trop Dis. 2016;10(2):e0004362. DOI: 10.1371/journal.pntd.0004362
Ntuku H.M, Ferrari G, Burri C, Tshefu A.K, Kalemwa D.M, Lengeler C. Feasibility and acceptability of injectable artesunate for the treatment of severe malaria in the Democratic Republic of Congo. Malar J. 2016;15:18. DOI: 10.1186/s12936-015-1072-x
Pohlig G, Bernhard S.C, Blum J, Burri C, Mpanya A, Lubaki J.P, Mpoto A.M, Munungu B.F, N'tombe P.M, Deo G.K, Mutantu P.N, Kuikumbi F.M, Mintwo A.F, Munungi A.K, Dala A, Macharia S, Bilenge C.M, Mesu V.K, Franco J.R, Dituvanga N.D, Tidwell R.R, Olson C.A. Efficacy and safety of pafuramidine versus pentamidine maleate for treatment of first stage sleeping sickness in a randomized, comparator-controlled, international phase 3 clinical trial. PLoS Negl Trop Dis. 2016;10(2):e0004363. DOI: 10.1371/journal.pntd.0004363
Vischer N, Pfeiffer C, Joller A, Klingmann I, Ka A, Kpormegbe S.K, Burri C. The good clinical practice guideline and its interpretation - perceptions of clinical trial teams in sub-Saharan Africa. Trop Med Int Health. 2016;21(8):1040-1048. DOI: 10.1111/tmi.12734
Ferrari G, Ntuku H.M, Burri C, Kitoto A.T, Duparc S, Hugo P, Mitembo D.K, Ross A, Ngwala P.L, Luwawu J.N, Musafiri P.N, Ngoie S.E, Lengeler C. An operational comparative study of quinine and artesunate for the treatment of severe malaria in hospitals and health centres in the Democratic Republic of Congo: the MATIAS study. Malar J. 2015;14:226. DOI: 10.1186/s12936-015-0732-1
Ferrari G, Ntuku H.M, Burri C, Kitoto A.T, Duparc S, Hugo P, Mitembo D.K, Ross A, Ngwala P.L, Luwawu N, Musafiri P.N, Ngoie S.E, Lengeler C. An operational comparative study of quinine and artesunate for the treatment of severe malaria in hospitals and health centres in The Democratic Republic of Congo: the MATIAS study. Trop Med Int Health, 2015;20(Suppl. 1):91. Abstracts of the 9th European Congress on Tropical Medicine and International Health, 6-10 September 2015, Basel, Switzerland
Conference Paper
Gajewski S, Burri C. Clinical research data management: solutions for low-resource settings. Trop Med Int Health, 2015;20(Suppl. 1):432-433
Conference Paper
Signorell A, Torrente M, Scherrer B, Mordt O.V, Strub-Wourgaft N, Tarral A, Burri C. Safety and efficacy of fexinidazole against rhodesiense human African trypanosomiasis: approach to conducting a clinical trial for a very rare, neglected disease. Trop Med Int Health, 2015;20(Suppl. 1):337. Abstracts of the 9th European Congress on Tropical Medicine and International Health, 6-10 September 2015, Basel, Switzerland
Conference Paper
Vischer N, Pfeiffer C, Burri C. Improving efficiency and quality in clinical trials in sub-Saharan Africa. Trop Med Int Health, 2015;20(Suppl. 1):125. Abstracts of the 9th European Congress on Tropical Medicine and International Health, 6-10 September 2015, Basel, Switzerland
Conference Paper
Burri C, Chappuis F, Brun R. Human African trypanosomiasis. In: Farrar J,Hotez P.J,Junghanss T,Kang G,Lalloo D,White N.J, eds. Manson's Tropical Diseases, 606-621. [Edinburgh]: Saunders, 2014
Book Section
Burri C, Ferrari G, Ntuku H.M, Kitoto A.T, Duparc S, Hugo P, Mitembo D.K, Lengeler C. Delayed anemia after treatment with injectable artesunate in the democratic republic of the Congo: a manageable issue. Am J Trop Med Hyg. 2014;91(4):821-823. DOI: 10.4269/ajtmh.14-0149
Burri C. Antiprotozoals for human African trypanosomiasis: the heart of darkness at dawn [Commentary]. Clin Invest. 2014;4(1):13-18. DOI: 10.4155/CLI.13.116
Journal Item
Williams J.R, Sprumont D, Hirtle M, Adebamowo C, Braunschweiger P, Bull S, Burri C, Czarkowski M, Fan C.T, Franck C, Gefenas E, Geissbuhler A, Klingmann I, Kouyate B, Kraehenbhul J.P, Kruger M, Moodley K, Ntoumi F, Nyirenda T, Pym A, Silverman H, Tenorio S. Consensus standards for introductory e-learning courses in human participants research ethics. J Med Ethics. 2014;40(6):426-428. DOI: 10.1136/medethics-2013-101572
Burri C, Ferrari G, Ntuku H.M, Mitembo D.K, Ngwala P.L, Luwawu J.J.N, Musafiri P.N, Ngoie S.E, Hugo P, Kitoto A.T, Lengeler C. Treatment of severe malaria: an operational comparison between quinine and artesunate for the treatment of severe malaria in seven health facilities in the democratic republic of the Congo - "Matias". Am J Trop Med Hyg, 2013;89(5 Suppl.):199
Conference Paper
Burri C. An alternative form of melarsoprol in sleeping sickness: is an old drug always the best basis for a new one? [Letter]. Trends Parasitol. 2012;28(9):354-355. DOI: 10.1016/j.pt.2012.06.002
Küpfer I, Schmid C, Allan M, Edielu A, Haary E.P, Kakembo A, Kibona S, Blum J, Burri C. Safety and efficacy of the 10-day melarsoprol schedule for the treatment of second stage rhodesiense sleeping sickness. PLoS Negl Trop Dis. 2012;6(8):e1695. DOI: 10.1371/journal.pntd.0001695
Fenner L, Gagneux S, Kabuya G, Stucki D, Kabuayi J.P, Borrell S, Frei R, Burri C, Kalemwa D, Egger M, Okiata J.P. Mycobacterium tuberculosis genetic diversity and drug resistance conferring mutations in the Democratic Republic of the Congo. East Afr Med J. 2011;88(12):409-415
Journal Article
Kümmerle A, Dodoo A.N.O, Olsson S, Van Erps J, Burri C, Lalvani P.S. Assessment of global reporting of adverse drug reactions for anti-malarials, including artemisinin-based combination therapy, to the WHO Programme for International Drug Monitoring. Malar J. 2011;10:57. DOI: 10.1186/1475-2875-10-57
Küpfer I, Hhary E.P, Allan M, Edielu A, Burri C, Blum J.A. Clinical presentation of T.b. rhodesiense sleeping sickness in second stage patients from Tanzania and Uganda. PLoS Negl Trop Dis. 2011;5(3):e968. DOI: 10.1371/journal.pntd.0000968
Probst-Hensch N, Tanner M, Kessler C, Burri C, Künzli N. Prevention--a cost-effective way to fight the non-communicable disease epidemic: an academic perspective of the United Nations High-level NCD Meeting. Swiss Med Wkly. 2011;141:w13266. DOI: 10.4414/smw.2011.13266
Schweizerisches Tropen- und Public Health-Institut. Eine vergessene Seuche: Erforschung und Bekämpfung der afrikanischen Schlafkrankheit am Swiss TPH. Basel: Schweizerisches Tropen- und Public Health-Institut, 2011
Book
Swiss Tropical and Public Health Institute. A forgotten epidemic: study and prevention of African sleeping sickness at the Swiss TPH. Basel: Swiss Tropical and Public Health Institute, 2011
Book
Brun R, Blum J, Chappuis F, Burri C. Human African trypanosomiasis. Lancet. 2010;375(9709):148-159. DOI: 10.1016/S0140-6736(09)60829-1
Burri C. Chemotherapy against human African trypanosomiasis: is there a road to success?. Parasitology. 2010;137(14):1987-1994. DOI: 10.1017/S0031182010001137
Matovu E, Küpfer I, Boobo A, Kibona S, Burri C. Comparative detection of trypanosomal DNA by loop mediated isotherma amplification and PCR from FTA cards spotted with patient blood. J Clin Microbiol. 2010;48(6):2087-2090. DOI: 10.1128/JCM.00101-10
Paine M.F, Wang M.Z, Generaux C.N, Boykin D.W, Wilson W.D, de Koning H.P, Olson C.A, Pohlig G, Burri C, Brun R, Murilla G.A, Thuita J.K, Barrett M.P, Tidwell R.R. Diamidines for human African trypanosomiasis. Curr Opin Investig Drugs. 2010;11(8):876-883
Blum J, Schmid C, Burri C, Hatz C, Olson C, Fungula B, Kazumba L, Mangoni P, Mbo F, Deo K, Mpanya A, Dala A, Franco J.R, Pohlig G, Zellweger M.J. Cardiac alterations in human African trypanosomiasis (T.b. gambiense) with respect to the disease stage and antiparasitic treatment. PLoS Negl Trop Dis. 2009;3(2):e383. DOI: 10.1371/journal.pntd.0000383
Burri C, Brun R. Human African trypanosomiasis. In: Cook G,Zumla A, eds. Manson's Tropical Diseases, 1307-1326. Edinburgh: Saunders, 2009
Book Section
Küpfer I, Burri C. Reflections on clinical research in sub-Saharan Africa. Int J Parasitol. 2009;39(9):947-954. DOI: 10.1016/j.ijpara.2009.02.021
Blum J.A, Zellweger M.J, Burri C, Hatz C. Cardiac involvement in African and American trypanosomiasis. Lancet Infect Dis. 2008;8(10):631-641
Brun R, Smith T, Maire N, Vounatsou P, Beck H.P, Lengeler C, Obrist B, Tanner M, Pluschke G, Burri C, Rudin W, Wyss K, Clary B, Hatz C, Marti H.P. Malaria Projektinformationen: Forschung und Dienstleistungen am Schweizerischen Tropeninstitut: Innovation - Validierung - Umsetzung. Basel: Schweiz. Tropeninstitut, 2008
Report
Pohlig G, Bernhard S, Blum J, Burri C, Kabeya A.M, Lubaki J.P.F, Mpoto A.M, Munungu B.F, Deo G.K.M, Mutantu P.N, Kuikumb F.M, Mintw A.F, Munungi A.K, Dala A, Macharia S, Bilenge C.M.M, Mesu V.K.B.K, Franco J.R, Dituvanga N.D, Olson C.A. Phase 3 trial of Pafuramidine Maleate (Db289), a novel, oral drug, for treatment of first stage sleeping sickness: safety and efficacy. Am J Trop Med Hyg. 2008;79(6):160-160
Journal Item
Blum J.A, Burri C, Hatz C, Kazumba L, Mangoni P, Zellweger M.J. Sleeping hearts: the role of the heart in sleeping sickness (human African trypanosomiasis). Trop Med Int Health. 2007;12(12):1422-1432
Blum J.A, Schmid C, Hatz C, Kazumba L, Mangoni P, Rutishauser J, la Torre A, Burri C. Sleeping glands? - The role of endocrine disorders in sleeping sickness (T.b. gambiense Human African Trypanosomiasis). Acta Trop. 2007;104(1):16-24. DOI: 10.1016/j.actatropica.2007.07.004
Blum J, Schmid C, Burri C. Clinical aspects of 2541 patients with second stage human African trypanosomiasis. Acta Trop. 2006;97(1):55-64
Schmid C, Richer M, Bilenge C.M, Josenando T, Chappuis F, Manthelot C.R, Nangouma A, Doua F, Asumu P.N, Simarro P.P, Burri C. Effectiveness of a 10-day melarsoprol schedule for the treatment of late-stage human African trypanosomiasis: confirmation from a multinational study (IMPAMEL II). J Infect Dis. 2005;191(11):1922-1931
Burri C, Stich G, Brun R. Current chemotherapy of human African trypanosomiasis. In: Maudlin I,Holmes P.H,Miles M.A, eds. The Trypanosomiases, 403-419. Wallingford: CABI Publishing, 2004
Book Section
Schmid C, Nkunku S, Merolle A, Vounatsou P, Burri C. Efficacy of 10-day melarsoprol schedule 2 years after treatment for late-stage gambiense sleeping sickness. Lancet. 2004;364(9436):789-790
Bodley A.L, Chakraborty A.K, Xie S, Burri C, Shapiro T.A. An unusual type IB topoisomerase from African trypanosomes. Proc Natl Acad Sci USA. 2003;100(13):7539-7544
Burri C, Brun R. Eflornithine for the treatment of human African trypanosomiasis. Parasitol Res. 2003;90(1):49-52
Journal Article
Burri C, Brun R. Human African trypanosomiasis. In: Cook G,Zumla A, eds. Manson's Tropical Diseases, 1303-1323. London: Harcourt Publishing, 2003
Book Section
Nenortas E, Kulikowicz T, Burri C, Shapiro T.A. Antitrypanosomal activity of pyrrolidinyl-substituted fluoroquinolones. Antimicrob Agents Chemother. 2003;47:3015-3017
Journal Article
Blum J, Burri C. Treatment of late stage sleeping sickness caused by T.b. gambiense: a new approach to the use of an old drug. Swiss Med Wkly. 2002;132(5-6):51-56
Legros D, Ollivier G, Gastellu-Etchegorry M, Paquet C, Burri C, Jannin J, Büscher P. Treatment of human African trypanosomiasis - present situation and needs for research and development.. Lancet Infect Dis. 2002;2(7):437-440
Journal Article
Blum J, Nkunku S, Burri C. Clinical description of encephalopathic syndromes and risk factors for their occurrence and outcome during melarsoprol treatment of human African trypanosomiasis. Trop Med Int Health. 2001;6(5):390-400
Brun R, Burri C, Gichuki C.W. The story of CGP 40 215: studies on the efficacy and pharmacokinetics in the African green monkey infected with Trypanosoma brucei rhodesiense. Trop Med Int Health. 2001;6(5):362-368
Journal Article
Brun R, Schumacher R, Schmid C, Kunz C, Burri C. The phenomenon of treatment failures in human African trypanosomiasis. Trop Med Int Health. 2001;6(11):906-914
Burri C, Keiser J. Pharmacokinetic investigations in patients from northern Angola refractory to melarsoprol treatment. Trop Med Int Health. 2001;6(5):412-420
Journal Article
Burri C. Are there new approaches to roll back trypanosomiasis? [Editorial]. Trop Med Int Health. 2001;6(5):327-329
Keiser J, Burri C. Evaluation of quinolone derivatives for antitrypanosomal activity. Trop Med Int Health. 2001;6(5):369-389
Keiser J, Stich A, Burri C. New drugs for the treatment of human African trypanosomiasis: research and development. Trends Parasitol. 2001;17(1):42-49
Burri C, Nkunku S, Merolle A, Smith T, Blum J, Brun R. Efficacy of new, concise schedule for melarsoprol in treatment of sleeping sickness caused by Trypanosoma brucei gambiense: a randomised trial. Lancet. 2000;355(9213):1419-1425
Keiser J, Burri C. Physico-chemical properties of the trypanocidal drug melarsoprol [Short communication]. Acta Trop. 2000;74(1):101-104
Keiser J, Erricsson Ö, Burri C. Investigations of the metabolites of the trypanocidal drug melarsoprol. Clin Pharmacol Ther. 2000;67(5):478-488. DOI: 10.1067/mcp.2000.105990
Onyango J.D, Burri C, Brun R. An automated biological assay to determine levels of the trypanocidal drug melarsoprol in biological fluids. Acta Trop. 2000;74(1):95-100
Nenortas E, Burri C, Shapiro T.A. Antitrypanosomal activity of fluoroquinolones. Antimicrob Agents Chemother. 1999;43(8):2066-2068
Bronner U, Brun R, Doua F, Ericsson O, Burri C, Keiser J, Miezan T.W, Boa Y.F, Rombo L, Gustafsson L.L. Discrepancy in plasma melarsoprol concentrations between HPLC and bioassay methods in patients with T. gambiense sleeping sickness indicates that melarsoprol is metabolized. Trop Med Int Health. 1998;3(11):913-917
Burri C, Bodley A.L, Shapiro T.A. Topoisomerases in kinetoplastids. Parasitol Today. 1996;12(6):226-231
Burri C, Blum J, Brun R. Alternative application of melarsoprol for treatment of T.b. gambiense sleeping sickness: preliminary results. Ann Soc Belg Med Trop. 1995;75(1):65-71
Burri C, Onyango J.D, Auma J.E, Burudi E.M.E, Brun R. Pharmacokinetics of melarsoprol in uninfected vervet monkeys. Acta Trop. 1994;58(1):35-49
Burri Christian. Pharmacological aspects of the trypanocidal drug melarsoprol. Basel: Univ. Basel, 1994. Doctoral Thesis, University of Basel, Faculty of Science
Thesis
Lun Z.R, Burri C, Menzinger M, Kaminsky R. Antiparasitic activity of diallyl trisulfide (Dasuansu) on human and animal pathogenic protozoa (Trypanosoma sp., Entamoeba histolytica and Giardia Lamblia) in vitro. Ann Soc Belg Med Trop. 1994;74(1):51-59
Burri C, Baltz T, Giroud C, Doua F, Welker H.A, Brun R. Pharmacokinetic properties of the trypanocidal drug melarsoprol. Chemotherapy. 1993;39(4):225-234
Burri C, Brun R. An in vitro bioassay for quantification of melarsoprol in serum and cerebrospinal fluid. Trop Med Parasitol. 1992;43(4):223-225